Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624880 · ClinicalTrials.gov registry record
COMT Activity and Hypnotizability
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 80
- Enrollment target
NCT04624880: Completed study, sponsored by Stanford University.
NCT04624880 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04624880 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to 40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use perioperatively, and may also be associated with hypnotizability or response to hypnotic analgesia. Analyzing COMT haplotypes from DNA extracted from saliva or blood using a giant magnetoresistive (GMR) nanotechnology platform may be faster, less expensive, and at least as accurate as pyrosequencing. This study aims to validate a multi-SNP point-of-care (POC) GMR assay for the rapid genotyping of SNPs predictive of COMT activity, and test the feasibility of using COMT activity as a biomarker for hypnotizability and/or response to hypnotic analgesia.
Primary Outcome
We will test the hypothesis that the four COMT SNPs (rs4680, rs4818, rs4633, and rs6269) can be detected on the GMR platform with 99% accuracy when compared to pyrosequencing
Interventions
- DEVICE Giant magnetoresistive sensor (GMR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2021-07-13 |
What the finished NCT04624880 record still lists
NCT04624880 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Giant magnetoresistive sensor (GMR) is the first listed.
NCT04624880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04624880 about?
NCT04624880 is a clinical study titled "COMT Activity and Hypnotizability". Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to 40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use perioperatively, and may also be associated with hypnotizability or response to hypnotic analgesia. Analyzing COMT h...
What is the current status of trial NCT04624880?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2021-01-13. Estimated completion is 2021-07-13.
What interventions are being tested in trial NCT04624880?
The interventions under investigation include: Giant magnetoresistive sensor (GMR) (DEVICE).
Who is sponsoring clinical trial NCT04624880?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI